Fapon, a frontrunner in the life sciences sector, is set to unveil its extensive range of in vitro diagnostic (IVD) solutions during WHX Labs Dubai 2026, which runs from February 10 to 13 at the Dubai World Trade Centre. With over 20 years of expertise and innovative technology at its core, Fapon is particularly showcasing its groundbreaking Alzheimer’s Disease blood testing solution among other key offerings. By enabling flexible collaboration models, Fapon aims to provide comprehensive localization support to its partners, which includes everything from technical guidance to local production, thereby enhancing the IVD industry in various regions worldwide.

Comprehensive Local Manufacturing Solutions

At the exhibition, Fapon will introduce its Local Manufacturing Solutions, which integrate various diagnostic platforms such as chemiluminescence immunoassay (CLIA), clinical biochemistry, lateral flow assay (LFA), and molecular diagnostics. These solutions feature a full-chain technology transfer, ensuring partners can access core raw materials and reagent solutions, along with open-system instruments, research and development expertise, and production methodologies. This holistic approach empowers local partners to establish their own industrial capabilities, stretching from R&D and production to eventual market commercialization, thus meeting the specific demands of regional healthcare.

Innovative Alzheimer’s Disease Testing

A standout feature of Fapon’s presentation is its advanced Alzheimer’s Disease blood testing solution, which offers a comprehensive array of raw materials and reagents essential for critical biomarkers like p-tau 217, p-tau 181, Aβ40, Aβ42, GFAP, and NfL. These biomarkers deliver exceptional sensitivity and specificity, closely correlating with existing diagnostic kits and established clinical tests. This capability enables IVD manufacturers globally to pursue the production of more accurate and reliable assays for Alzheimer’s assessments, significantly contributing to better patient outcomes.

High-Performance Diagnostic Tools

Fapon will also showcase its all-in-one chemiluminescence solution, featuring the Shine series of CLIA analyzers, which cater to various throughput levels ranging from 120 T/h to 900 T/h. Accompanying these analyzers are over 70 unique reagent solutions and essential raw materials. Additionally, Fapon’s portfolio includes high-performance raw materials like recombinant quality controls and calibrators for tests relating to RF, HbA1c, and HIV, as well as LAMP solutions geared towards rapid molecular diagnostics. This robust upstream support reflects Fapon’s commitment to advancing diagnostic development.

A Global Commitment to Healthcare Innovation

With state-of-the-art facilities covering an area exceeding 100,000 m² and a global network of research and development and manufacturing, Fapon is dedicated to delivering innovative, locally relevant solutions to the healthcare market. Currently, the company serves more than 70 countries and collaborates with over 2,500 organizations globally. Fapon’s unwavering focus on building partnerships underscores its mission to promote regional healthcare advancements and improve patient care worldwide.

Through its cutting-edge AI-driven approach combined with a thorough integration of experimental processes, Fapon is setting new standards in the fields of diagnostics and therapeutics. This model significantly accelerates the discovery of novel biomarkers and enhances their practical application, solidifying the company’s position at the forefront of health management and precision medicine development. For more information, visit Fapon’s official website.